Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10207
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLy, John Ven
dc.contributor.authorZavala, Jorge Aen
dc.contributor.authorDonnan, Geoffrey Aen
dc.date.accessioned2015-05-15T23:35:04Z
dc.date.available2015-05-15T23:35:04Z
dc.date.issued2006-08-01en
dc.identifier.citationExpert Opinion On Pharmacotherapy; 7(12): 1571-81en
dc.identifier.govdoc16872260en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10207en
dc.description.abstractThe administration of oral aspirin within 48 h and tissue plasminogen activator within 3 h of ischaemic stroke onset remain the only treatments that have been shown to have clinical benefit. There has been much excitement about neuroprotection over the last two decades, as it may minimise the harmful effects of ischaemic neuronal damage. Although each step along the ischaemic cascade offers a potential target for therapeutic intervention, and neuroprotection has shown benefit in animal studies, this has been difficult to translate to humans. Some hope has been offered by the recent finding that the free radical scavenger NXY-059 may improve outcomes in patients presenting within 6 h of onset of ischaemic stroke. There is logic to the idea that neuroprotection may be most effective when reperfusion has occurred with thrombolysis, as the neuroprotectant will have greater access to ischaemic tissue and the opportunity is presented to minimise free radical-mediated reperfusion injury. Numerous studies in animal models support this view, but the concept has not, as yet, been rigorously tested in humans.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherBenzenesulfonates.pharmacology.therapeutic useen
dc.subject.otherBrain.drug effects.pathologyen
dc.subject.otherBrain Ischemia.drug therapy.pathologyen
dc.subject.otherDrug Therapy, Combinationen
dc.subject.otherFibrinolytic Agents.therapeutic useen
dc.subject.otherFree Radical Scavengers.pharmacology.therapeutic useen
dc.subject.otherGABA Agonists.pharmacology.therapeutic useen
dc.subject.otherHumansen
dc.subject.otherNeuroprotective Agents.pharmacology.therapeutic useen
dc.subject.otherNitrogen Oxides.pharmacology.therapeutic useen
dc.subject.otherPiperidines.pharmacology.therapeutic useen
dc.subject.otherRandomized Controlled Trials as Topicen
dc.subject.otherSodium Channel Blockers.pharmacology.therapeutic useen
dc.subject.otherStroke.drug therapy.pathologyen
dc.subject.otherThiazoles.pharmacology.therapeutic useen
dc.subject.otherThrombolytic Therapyen
dc.subject.otherTime Factorsen
dc.subject.otherTissue Plasminogen Activator.therapeutic useen
dc.titleNeuroprotection and thrombolysis: combination therapy in acute ischaemic stroke.en
dc.typeJournal Articleen
dc.identifier.journaltitleExpert opinion on pharmacotherapyen
dc.identifier.affiliationNational Stroke Research Institute, Level 1, Neurosciences Building, Austin Health, University of Melbourne, 300 Waterdale Road, Heidleberg Heights, Victoria 3081, Australiaen
dc.identifier.doi10.1517/14656566.7.12.1571en
dc.description.pages1571-81en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/16872260en
dc.type.austinJournal Articleen
local.name.researcherDonnan, Geoffrey A
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Feb 24, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.